Article Text

Download PDFPDF

Letter to the editor
Effects of omalizumab in Aspergillus-associated airway disease
  1. L A Pérez-de-Llano1,
  2. M C Vennera2,
  3. A Parra3,
  4. J Guallar4,
  5. M Marin4,
  6. O Asensio5,
  7. P Ausin6,
  8. L Borderías7,
  9. C Fernández8,
  10. C Granel9,
  11. A Pérez-Pimiento10,
  12. M Rubio11
  1. 1Pneumology, Hospital Xeral-Calde, Lugo, Spain
  2. 2Pneumology and Respiratory Allergy, Hospital Clinic, CIBERES, Barcelona, Spain
  3. 3Allergology, Centro Hospitalario Universitario, Coruña, Spain
  4. 4Pneumology, Hospital General, Castellón, Spain
  5. 5Pediatry, Corporació Sanitaria Parc Tauli, Sabadell, Spain
  6. 6Pneumology, Hospital del Mar, Barcelona, Spain
  7. 7Pneumology, Hospital San Jorge, Huesca, Spain
  8. 8Allergology, Hospital 12 de Octubre, Madrid, Spain
  9. 9Allergology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
  10. 10Allergology, Hospital Universitario Puerta del Hierro Majadahonda, Madrid, Spain
  11. 11Allergology, Hospital General Universitario Gregorio Marañon, Madrid, Spain
  1. Correspondence to Luis A Pérez de Llano, Pneumology Service, Hospital Xeral-Calde, c/Dr Ochoa, s/n, Lugo 27004, Spain; eremos26{at}

Statistics from

The clinical spectrum of Aspergillus-associated airway diseases (AAAD) includes Aspergillus-induced asthma, allergic bronchopulmonary aspergillosis (ABPA) and bronchocentric granulomatosis. Corticosteroids are almost always used to suppress the immunological response to the fungal antigens.1 Although there are no evidence-based alternative treatment options besides steroids, the well-known adverse effects of these drugs have prompted clinicians to look beyond this standard practice and several cases of ABPA patients with very positive outcomes after omalizumab therapy have been recently published.2–6

We recruited 18 patients (13 women; mean age 49±17 years) with AAAD (2 of them had been previously diagnosed with cystic fibrosis) from 11 Spanish hospitals. All of them had been treated with omalizumab for at least 16 weeks and they were receiving inhaled corticosteroids (daily dose 1351±554 μg budesonide or its equivalent) and a long-acting β2 agonist at the moment of omalizumab initiation. Seventeen patients were being treated with oral corticosteroids at a median daily dose of 16 mg prednisone or its equivalent (IQR 6–28) and 10 with itraconazole. The mean number of albuterol puffs per day was 3.5 (range 1–8). Prior to omalizumab administration, IgE levels were (median (IQR)) 698 IU/ml (478–977) and the median absolute count of eosinophils in blood was 610 mm3 (317–1015). Sixteen of the 18 patients had CT-diagnosed bronchiectasis and fleeting pulmonary opacities were identified in 10 of them. All patients showed a delayed positive skin test for Aspergillus and 17 also developed an immediate response. Serum Aspergillus-specific IgE was found in all patients and precipitating antibodies in serum were observed in 10.

Omalizumab-treated patients were followed up for a median of 36 weeks (IQR, 28–42). The mean dose of omalizumab per week was 608±108 mg. No significant adverse effects were observed. The treatment was discontinued in five patients due to a lack of response and in another patient because of a positive test for pregnancy. The clinical and functional effects of omalizumab are summarised in table 1.

Table 1

Functional and clinical outcomes following omalizumab therapy

In this series, the largest reported to date, omalizumab has demonstrated a beneficial effect in reducing symptoms and exacerbations in a group of patients with AAAD. It also seems to improve pulmonary function even when oral corticosteroids were reduced or discontinued. Given the retrospective nature of this study and the small number of cases analysed, the results must be interpreted with caution. Although all patients met the criteria of APBA proposed by Rosenberg,7 the differentiation between this entity and Aspergillus-induced asthma is problematic, so we decided to blanket them under the term ‘Aspergillus-associated airway disease’. While the pathogenesis of ABPA remains not fully understood, IgE has been advocated as a key pathogenic mechanism of the disease. Since the total serum IgE level is a marker of immunological activity in ABPA, the attenuation of the hyper-IgE response seems to be a reasonable target. Further studies are warranted to clarify the utility of omalizumab in AAAD, especially in ABPA.



  • Funding LAPL, MCV and LB have received payment from Novartis Farmaceútica for lectures, consultancy and support for travelling to meetings. AP has received support from Novartis Farmaceútica for lectures and MR for travelling to meetings. JG, MM, OA, PA, CF, CG and AP-P have no conflicts of interest.

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.